Medical Developments International (ASX:MVP) - CEO, Brent MacGregor
CEO, Brent MacGregor
Source: Brent MacGregor via LinkedIn
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medical Developments International (MVP) shares dropped into the red after the company reported a $12.6 million loss during the 2021 financial year
  • The loss was driven by goodwill impairment charges, stemming from slow progress on its CSIRO project and a “difficult” period for the respiratory segment
  • Gross revenue grew nine per cent on the prior corresponding period, from $23.6 million to $25.7 million
  • Medical Developments International shares closed down 3.23 per cent to trade at $3.90 on August 25

Medical Developments International (MVP) shares dropped into the red after the company reported a $12.6 million loss during the 2021 financial year.

The company’s slim profits from last year, which totalled $400,000, were hampered further by goodwill impairment charges on its CSIRO project and medical devices segment.

MVP is in the process of developing alternative manufacturing methods for generic Active Pharmaceutical Ingredients in the ‘Continuous Flow Technology Project’ with Commonwealth research agency, CSIRO.

The company said progress on the project had been slower than anticipated and therefore failed to secure licences or commercial-scale production level estimates.

“As a result, MVP has booked a pre-tax impairment provision for $4.3 million in relation to the capitalised development costs on the basis that future economic benefit is not assured,” the company said in a statement.

MVP affirms it remains confident in the project and will continue to work with CSIRO.

Meanwhile, MVP said COVID-19 had made it a “difficult” period for its respiratory sales due to a milder flu season, resulting in an FY21 impairment charge of $4.7 million.

Despite incurring a loss, the ASX-lister said it anticipated strong sales growth in FY22 driven by its expansion into Europe.

Gross revenue grew nine per cent on the prior corresponding period, from $23.6 million to $25.7 million.

Medical Developments International shares closed down 3.23 per cent to trade at $3.90 on August 25.

MVP by the numbers
More From The Market Online
Stem cell concept

Mesoblast dips on ‘belief’ it’s not subject to US tariffs – despite Singaporean lab

Mesoblast (ASX:MSB) has seen shares fall just shy of -3% heading into lunchtime trades despite apparent…
Children's hospital concept

Mesoblast kicks off treatment for first 3 kids with graft-host disease. So why are shares down?

otCopper favourite Mesoblast (ASX:MSB) has announced it's begun treating the first 3 children with skin graft-versus-host…
CSL Limited logo

CSL survives a brutal sell-off but dips on US tariff response as investors eye pharma risk

CSL Ltd (ASX:CSL) has seen shares fall nearly half a percent in afternoon trades on Thursday…
Fisher & Paykel

Fisher & Paykel shrugs off red Thursday as investors satisfied tariff risks under control

Perhaps surprisingly, FIsher & Paykel Healthcare (ASX:FPH) – a company that produces around 40% of its…